載入...
Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma
The outcomes of patients treated with surgery for early stage pancreatic ductal adenocarcinoma (PDAC) are variable with median survival ranging from 6 months to more than 5 years. This challenge underscores an unmet need for developing personalized medicine strategies to refine the current treatment...
Na minha lista:
| 發表在: | PLoS One |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Public Library of Science
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4527782/ https://ncbi.nlm.nih.gov/pubmed/26247463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0133562 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|